MSF response to negotiations on an India-EU free trade agreement (FTA) regarding harmful intellectual property (IP) provisions

The EU initiative does not address the shortcomings of the current compulsory licensing mechanism, undermines existing TRIPS flexibilities and risks delaying the urgent adoption of the TRIPS Waiver proposal.

In their statement at a recent virtual event titled "COVID-19 and Vaccine Equity: What Can the WTO Contribute?" held on 14 April 2021, the EU Commission continued to defend a position that leaves a handful of pharmaceutical companies ...